---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021407"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:46:10.504663+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%

## Summary
- Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
- Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.
- Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.
- Amendment to Section 2.07 effective immediately on July 24, 2025.

## SEC filing metadata
- accession: 0001641172-25-021407
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021407
- JSON: https://secwatch.observer/filing/0001641172-25-021407.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021407.txt

## Key facts
- Governance Changes
  Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).
  - Change: bylaw amendment
  - Effective: 2025-07-24
  source text: On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.